


Tubulin polymerization-IN-35

| | |
|---------------------------|---|
| Cat. No.: | HY-151396 |
| Molecular Formula: | C ₃₁ H ₃₅ N ₃ O ₅ |
| Molecular Weight: | 529.63 |
| Target: | Microtubule/Tubulin |
| Pathway: | Cell Cycle/DNA Damage; Cytoskeleton |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|-------------------------------------|--|------------|--|----------------|------------|------------------|------|---------|--|
| Description | Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line ^[1] . | | | | | | | | |
| IC₅₀ & Target | [1,2]oxazoloisoindoles tubulin polymerization ^[1] | | | | | | | | |
| In Vitro | <p>Tubulin polymerization-IN-35 (compound 17j) (10 nM-100 μM; 72 h) has antiproliferative activity against 9 NCI subpanels (leukemia, non-small-cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate, breast) with GI₅₀s ranging from 0.24 μM to 23.4 μM, and a mean graph_mid point (MG_MID) values of 1.32 μM^[1].</p> <p>Tubulin polymerization-IN-35 (0.15-10 μM; 72 h) shows potent growth inhibitory effects on different lymphoma lines, and demonstrates high selectivity against the VL51 cell line (Marginal zone lymphoma, IC₅₀=0.15 μM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Marginal zone lymphoma, mantle cell lymphoma, activated B-cell like diffuse large B cell lymphoma, germinal center B-cell-like diffuse large B cell lymphoma cells</td> </tr> <tr> <td>Concentration:</td> <td>0.15-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited different lymphomas, with IC₅₀s of 0.15 μM (Marginal zone lymphoma); 0.5 μM (mantle cell lymphoma); 0.6 μM (activated B-cell like diffuse large B cell lymphoma); 0.7 μM (germinal center B-cell-like diffuse large B cell lymphoma), respectively.</td> </tr> </table> | Cell Line: | Marginal zone lymphoma, mantle cell lymphoma, activated B-cell like diffuse large B cell lymphoma, germinal center B-cell-like diffuse large B cell lymphoma cells | Concentration: | 0.15-10 μM | Incubation Time: | 72 h | Result: | Inhibited different lymphomas, with IC ₅₀ s of 0.15 μM (Marginal zone lymphoma); 0.5 μM (mantle cell lymphoma); 0.6 μM (activated B-cell like diffuse large B cell lymphoma); 0.7 μM (germinal center B-cell-like diffuse large B cell lymphoma), respectively. |
| Cell Line: | Marginal zone lymphoma, mantle cell lymphoma, activated B-cell like diffuse large B cell lymphoma, germinal center B-cell-like diffuse large B cell lymphoma cells | | | | | | | | |
| Concentration: | 0.15-10 μM | | | | | | | | |
| Incubation Time: | 72 h | | | | | | | | |
| Result: | Inhibited different lymphomas, with IC ₅₀ s of 0.15 μM (Marginal zone lymphoma); 0.5 μM (mantle cell lymphoma); 0.6 μM (activated B-cell like diffuse large B cell lymphoma); 0.7 μM (germinal center B-cell-like diffuse large B cell lymphoma), respectively. | | | | | | | | |

REFERENCES

[1]. Marilia Barreca, et al. Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas, European Journal of Medicinal Chemistry. 2022, 114744, ISSN 0223-5234.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA